Observational Study on CMV in Lung Transplant Recipients
This study is looking at how the Cytomegalovirus (CMV) virus affects people who have received a lung transplant. Researchers will follow your body's immune response to CMV by testing for the virus. The main goal is to see if having CMV Immunoglobulin (IgG) — a type of antibody that shows you've been exposed to CMV — is linked to certain outcomes up to one year after your transplant. You might be able to join if you are between 18 and 75 years old, are getting a lung transplant, and have tested positive for CMV IgG before your transplant. This is an observational study with a planned enrollment of 100 participants.
- Study design
- This is an observational study with 100 planned participants. It is not specified if it is randomized or blinded.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will follow participants for up to one year to measure positive CMV Immunoglobulin (IgG).
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Yoichiro Natori, MD · PRINCIPAL_INVESTIGATOR · University of Miami
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Positive CMV Immunoglobulin (IgG) positive lung transplantUp to 1 year
Positive CMV Immunoglobulin (IgG) measured by IU/ml